Unexpected Abundance of Pathological Tau in Progressive Supranuclear Palsy White Matter

Victoria Zhukareva, PhD,1 Sonali Joyce, BS,1 Teresa Schuck, BS,1 Vivianna Van Deerlin, MD, PhD,1 Howard Hurtig, MD,2 Roger Albin, MD,3,4 Sid Gilman, MD, FRCP,3 Steven Chin, MD,5 Bruce Miller, MD,6 John Q. Trojanowski, MD, PhD,1 and Virginia M-Y. Lee, PhD1

Objective: To investigate whether biochemical insoluble tau with 4 (4R) and/or 3 (3R) microtubule-binding repeats accumulate in white as well as gray matter in progressive supranuclear palsy (PSP), a neurodegenerative tauopathy.

Methods: To assess tau pathology in PSP white matter, we combined Western blot (WB) and immunohistochemical methods to analyze 23 autopsy-confirmed PSP brains.

Results: WBs showed an unexpected abundance of insoluble tau in white and gray matter of PSP brains, but biochemical tau pathology in white matter was not correlated with immunohistochemistry using the same panel of epitope-specific anti-tau antibodies used for WB. Despite heterogeneity in the representation of pathological 3R and 4R tau isoforms in cortical versus subcortical regions, biochemically detectable white matter tau pathology is a constant feature of PSP.

Interpretation: These studies show additional similarities between PSP and corticobasal degeneration, but unlike corticobasal degeneration, more abundant white matter tau pathology in PSP is detectable by WB than by immunohistochemistry. The differential detection of abnormal tau by biochemistry versus microscopy in PSP may reflect distinct pathological mechanisms, and elucidation of these processes will augment efforts to develop better strategies for the diagnosis and treatment of PSP and related neurodegenerative tauopathies.

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by postural instability, rigidity, parkinsonism, supranuclear gaze palsy, and cognitive abnormalities, including dementia, in association with prominent cortical and subcortical neuronal and glial tau pathology (reviewed in Cairns and colleagues,1 Dickson,2 Forman and colleagues,3 and McKhann and colleagues4). Thus, PSP shares phenotypic features with frontotemporal dementias and movement disorders that are classified as tauopathies.1–4 Tau phosphoproteins bind to microtubules, and their function is to promote the assembly and stability of microtubules, thereby playing a pivotal role in maintaining axonal transport (reviewed in Buee and colleagues,5 Lee and colleagues,6 and Roy and colleagues7). In the adult human central nervous system, six tau isoforms are produced by alternative splicing. Alternative splicing of exons 2 and 3 results in the insertion of 0 (0N), 1 (1N), or 2 (2N) 29-amino acid long motifs near the amino terminus, whereas splicing of exon 10 results in the inclusion of either 3 (3R) or 4 (4R) microtubule-binding domains in the carboxy terminus. From largest to smallest, the brain tau isoforms are designated 4R2N, 3R2N, 4R1N, 3R1N, 4R0N, and 3R0N, respectively. The pathological filamentous tau inclusions in PSP are composed of aberrantly phosphorylated tau proteins, but there is a preferential accumulation of abnormal 4R tau isoforms in PSP.1–4 These tau inclusions are formed by neurons, astrocytes, and oligodendrocytes in PSP, but similar inclusions also occur in corticobasal degeneration (CBD), a 4R tauopathy that shares genetic and clinical features with PSP, although unlike PSP, there is abundant white matter tau pathol-

From the 1Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research; 2Department of Neurology, University of Pennsylvania, Philadelphia, PA; 3Michigan Alzheimer’s Disease Research Center, University of Michigan Health Center; 4Ann Arbor Affairs Medical Center Geriatric Research Education and Clinical Center, Ann Arbor, MI; 5Department of Pathology, University of Utah, Salt Lake City, UT; and 6Memory and Aging Center of the University of California, San Francisco, CA.

Received Jan 5, 2006, and in revised form Apr 25. Accepted for publication May 9, 2006.

This article includes supplementary materials available via the Internet at http://www.interscience.wiley.com/pages/0364-5134/suppmat

Published online Jul 5, 2006, in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/ana.20916

Address correspondence to Dr Lee, The Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, HUP/ Maloney 3, 3600 Spruce Street, Philadelphia, PA 19104-4283. E-mail: vmylee@mail.med.upenn.edu

© 2006 American Neurological Association

Published by Wiley-Liss, Inc., through Wiley Subscription Services
However, because the presence of pathologically insoluble tau detected with biochemical methods in a neurodegenerative tauopathy may not be evident microscopically as tau inclusions, we examined this possibility in PSP. To do this, we analyzed tau pathology in 23 clinically and neuropathologically confirmed PSP cases with respect to the distribution of tau lesions and the biochemical profile of abnormal tau isoforms in multiple cortical gray and white matter regions, as well as subcortical brain regions. Remarkably, these studies demonstrated an unexpected abundance of tau pathology in white matter that was detected biochemically, but not by microscopic examination using the same panel of epitope-specific tau antibodies. Although this reflects incompletely understood differences in the pathological modifications of tau in PSP, we anticipate that clarification of this conundrum will accelerate efforts to improve the diagnosis and treatment of PSP and related tauopathies.

**Materials and Methods**

**Brain Tissue Samples**

Brain tissue samples used in this study were obtained from the Alzheimer’s Disease Centers of the University of Pennsylvania School of Medicine, the Columbia University College of Physicians and Surgeons, the University of Michigan, and the University of California San Francisco. The diagnostic clinical and neuropathological assessment of all cases was performed according to accepted guidelines, and patients with PSP, Alzheimer’s disease (AD), and CBD met consensus criteria for clinical and neuropathological diagnosis as described previously.

<table>
<thead>
<tr>
<th>PSP Cases</th>
<th>PMI (hr)</th>
<th>Brain Weight (gm)</th>
<th>Sex</th>
<th>Onset</th>
<th>Duration</th>
<th>Dementia</th>
<th>Family History</th>
<th>4R/3R Ratio in Cortex</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>9.5</td>
<td>1,185</td>
<td>M</td>
<td>63</td>
<td>10</td>
<td>++</td>
<td>No</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>2</td>
<td>8.0</td>
<td>1,580</td>
<td>M</td>
<td>46</td>
<td>2</td>
<td>+</td>
<td>Yes</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>3</td>
<td>12.0</td>
<td>1,185</td>
<td>F</td>
<td>79</td>
<td>2</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>4</td>
<td>19.0</td>
<td>1,240</td>
<td>F</td>
<td>68</td>
<td>7</td>
<td>+</td>
<td>No</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>5</td>
<td>6.5</td>
<td>1,247</td>
<td>F</td>
<td>65</td>
<td>7</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>6</td>
<td>10.5</td>
<td>1,380</td>
<td>M</td>
<td>69</td>
<td>4</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>7</td>
<td>4.5</td>
<td>1,190</td>
<td>F</td>
<td>62</td>
<td>7</td>
<td>++</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>8</td>
<td>19.0</td>
<td>1,324</td>
<td>F</td>
<td>67</td>
<td>11</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>9</td>
<td>19.5</td>
<td>1,308</td>
<td>M</td>
<td>68</td>
<td>6</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>10</td>
<td>10.0</td>
<td>1,136</td>
<td>F</td>
<td>80</td>
<td>2</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>11</td>
<td>5.0</td>
<td>1,340</td>
<td>M</td>
<td>71</td>
<td>10</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>12</td>
<td>5.5</td>
<td>1,160</td>
<td>F</td>
<td>71</td>
<td>8</td>
<td>+</td>
<td>Yes</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>13</td>
<td>6.0</td>
<td>1,170</td>
<td>F</td>
<td>68</td>
<td>7</td>
<td>++</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>14</td>
<td>10.0</td>
<td>1,450</td>
<td>M</td>
<td>74</td>
<td>7</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>15</td>
<td>NA</td>
<td>1,276</td>
<td>F</td>
<td></td>
<td></td>
<td></td>
<td>Yes</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>16</td>
<td>4.0</td>
<td>1,430</td>
<td>M</td>
<td>75</td>
<td>9</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>17</td>
<td>6.0</td>
<td>1,060</td>
<td>M</td>
<td>81</td>
<td>6</td>
<td>++</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>18</td>
<td>16.5</td>
<td>1,064</td>
<td>F</td>
<td>79</td>
<td>11</td>
<td>++</td>
<td>No</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>19</td>
<td>4.0</td>
<td>1,234</td>
<td>F</td>
<td>66</td>
<td>6</td>
<td>++</td>
<td>Yes</td>
<td>4R=3R</td>
</tr>
<tr>
<td>20</td>
<td>2.0</td>
<td>1,350</td>
<td>M</td>
<td>81</td>
<td>15</td>
<td>++</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>21</td>
<td>NA</td>
<td>1,240</td>
<td>M</td>
<td>63</td>
<td>4</td>
<td>++</td>
<td>Yes</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>22</td>
<td>2.0</td>
<td>1,332</td>
<td>F</td>
<td>71</td>
<td>6</td>
<td>++</td>
<td>Yes</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>23</td>
<td>7.0</td>
<td>1,332</td>
<td>F</td>
<td>68</td>
<td>4</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>CBD 1</td>
<td>6.5</td>
<td>1,141</td>
<td>F</td>
<td>64</td>
<td>7</td>
<td>+</td>
<td>No</td>
<td>4R&gt;3R</td>
</tr>
<tr>
<td>CBD 2</td>
<td>5.0</td>
<td>1,182</td>
<td>F</td>
<td>62</td>
<td>8</td>
<td>+</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>AD 1</td>
<td>4.5</td>
<td>1,019</td>
<td>F</td>
<td>79</td>
<td>8</td>
<td>++++</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>AD 2</td>
<td>8.0</td>
<td>1,062</td>
<td>M</td>
<td>80</td>
<td>6</td>
<td>++++</td>
<td>No</td>
<td>4R=3R</td>
</tr>
<tr>
<td>AD 3</td>
<td>5.0</td>
<td>1,100</td>
<td>M</td>
<td>79</td>
<td>5</td>
<td>++++</td>
<td>No</td>
<td>4R=3R</td>
</tr>
</tbody>
</table>

Twenty-three progressive supranuclear palsy (PSP), two corticobasal degeneration (CBD), and three Alzheimer’s disease (AD) patients were used for this study. In 21 of 23 cases, tau haplotypes were identified as H1/H1 and A0/A0 (data not shown). Family members other than a proband were diagnosed with neurodegenerative disorder. PMI = postmortem interval, hours; NA = information is not available; + = mild cognitive impairment; ++ = progressive dementia, ++++ = severe dementia.
Fig 1. Comparative immunohistochemical (IHC) analysis of tau pathology in progressive supranuclear palsy (PSP). Single- and double-label immunofluorescence staining to show the individual localization (A, B) and coexpression (C, overlay) of phosphorylation-dependent (Pd) PHF1 and phosphorylation-independent (P) N-tau epitopes in frontal cortex and medulla of PSP brains. Numerous PHF1 (red) and N-tau-positive (green) lesions were detected in the frontal cortex and medulla from two PSP cases (1 and 2). Although individual immunolabeling with PHF1 or N-tau showed numerous tau inclusions throughout the cortical gray matter (arrows; A, B), both tau epitopes were colocalized only to a small subset of cells (arrowheads; C, overlay). In comparison with N-tau antibodies, PHF1 labeled less tau inclusions. In the cortical white matter, PHF1 and N-tau immunoreactivity was confined to a subset of single-labeled threadlike structures and to sparsely distributed glial cells. In medulla, colocalization of PHF1 and N-tau epitopes varied from partial overlap in a subset of neurons (Case 1) to numerous double-labeled cells (Case 2).
Immunohistochemistry

Tissue samples were collected at autopsy and fixed in 10% neutral-buffered formalin. The brain regions examined included frontal, temporal, parietal, and occipital lobes; cerebellum; basal ganglia; and the brainstem after samples were paraffin embedded and processed for neuropathological assessment. Also, frozen tissue from areas adjacent to blocks of frozen brain used for biochemical analyses (see later) were similarly fixed in neutral-buffered formalin, paraffin embedded, and examined as described here and in previous studies.9,12,14–16,18 “To do this, we cut 6μm-thick sections and assessed them with and without antigen retrieval methods (eg, with formic acid [FA] pretreatment) for the presence of tau pathology using a panel of previously described epitope-specific and other tau antibodies9,12,14–19 including the phosphorylation-independent (P) rabbit polyclonal antianti-

Biochemical and Quantitative Western Blot Analyses

Frozen tissue samples from multiple cortical and subcortical brain regions of most cases were used for the biochemical analysis. Gray and white matter regions were dissected and processed separately as described previously.9,12–14,18,19 Soluble and sarkosyl-insoluble tau proteins were prepared and dephosphorylated using alkaline phosphatase from Escherichia coli (Sigma, St. Louis, MO), as described previously.9,12,14,16–18 To do this, we cut 6μm-thick sections and assessed them with and without antigen retrieval methods (eg, with formic acid [FA] pretreatment) for the presence of tau pathology using a panel of previously described epitope-specific and other tau antibodies including the phosphorylation-independent (P) rabbit polyclonal anti-

Sequential Extraction of Tau Proteins

Selected brain areas were used for the sequential extraction of tau proteins with buffers/solutions of increasing stringency, as described previously.12,13,18,19 The following buffers with a mixture of protease inhibitors were used: (1) high-salt buffer (0.75M NaCl, 50mM tris(hydroxymethyl)aminomethane [Tris] buffer, pH 7.4; (2) 1% Triton X-100 in Buffer 1 (Sigma); (3) radioimmunoprecipitation assay buffer (0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 2M EDTA, 150mM NaCl, 50mM Tris buffer, pH 8.0); (4) 2% SDS; and (5) 80% FA. Each extraction step was repeated twice. After each extraction, samples were spun at 45,000g for 30 minutes at 4°C, after which supernatants were collected and subjected to Western blot analysis. Protein concentrations were adjusted between samples from each extraction.

Apolipoprotein Genotyping and Tau Haplotype Analyses

DNA was isolated from brain tissue using a commercial kit (Qiagen, Valencia, CA). Apolipoprotein E genotyping was performed by using a previously described polymerase chain reaction restriction fragment length polymorphism method.14,20 Tau gene (microtubule-associated protein tau [MAPT]) haplotype analysis was performed by polymerase chain reaction amplification of exon 9, followed by restriction digestion with HpaII and HpyCH4IV to genotype for the three known polymorphisms of exon 9 that segregate with the known major MAPT haplotypes.21,22

Results

Immunohistochemical Distribution of Tau Pathology in Progressive Supranuclear Palsy Brains

The distribution of tau lesions in cortical and subcortical regions of PSP brains has been well described, and the IHC observations here concurred with data from previous studies as illustrated in four representative PSP cases showing morphologically evident tau lesions that were more abundant in gray versus white matter regions (data not shown), but brainstem and basal ganglia were most affected. This distribution was confirmed in Gallyas-stained preparations, and these findings contrasted with comparable IHC data from CBD brains wherein cortical, as well as subcortical, white matter showed abundant tau pathology by light microscopy (data not shown). Double-immunofluorescence IHC using P1 N-tau (green) and P1 PHF1 (red) antibodies (Fig 1) showed that neuronal and glial tau inclusions in PSP were immunopositive for both antibodies, al-
Fig 2. Quantitative Western blot analysis of pathological tau proteins in progressive supranuclear palsy (PSP). Aliquots of sarkosyl-insoluble fractions from multiple brain regions were dephosphorylated and resolved on 7.5% SDS-PAGE. Mixture of six recombinant human tau proteins (Rt) were used as standards. To estimate total insoluble tau pool, we probed nitrocellulose replicas with a mixture of monoclonal antibodies (MAbs) T14 and T46. (A). Brain region-specific distribution of pathological tau in four PSP cases. The amounts of insoluble tau were variable among cases, but they were consistently higher in cortical white matter of PSP brains. (B). Quantitative assessment of sarkosyl-insoluble tau in different brain regions. For quantitative Western blot analysis, anti–mouse [I-125]-IgG was used, and quantitative data were generated using ImageQuant analysis. Each bar represents a relative amount of insoluble tau isolated from 1gm of PSP brain tissue as a percentage of a total amount of the latter in PSP basal ganglia. (C). The nitrocellulose replica here was subjected to Western blot analysis using a mixture of MAbs, Tau14 and Tau46 (top panels), after which the same membrane was stripped and reprobed with rabbit polyclonal E10-specific tau antibody that selectively recognizes all 4R tau isoforms in the PSP samples and in Rt mixture (bottom panels). (D). Immunohistochemical (IHC) analysis of two representative PSP cases with similar levels of pathological 4R and 3R (4R>3R) isoforms or predominantly 4R tau (4R>3R) isoforms. BG = basal ganglia; Ctx = cortex; Fg = frontal cortex, gray matter; Fw = white matter; M1, 2, 3 = medulla levels 1, 2, and 3 dissected for study as per the diagram in Figure 3; Og = occipital cortex, gray matter; Ow = occipital cortex, white matter; P = pons; Pg = parietal cortex, gray matter; Pw = parietal cortex, white matter; Tg = temporal cortex, gray matter; Tw = temporal cortex, white matter.
though PHF1 and N-tau immunoreactivity only colocalize about 25 to 50% of the time, and the N-tau antibody generally detected more tau lesions than PHF1.

Biochemical Assessment of Pathological Tau in Progressive Supranuclear Palsy

Western blot analysis of sarkosyl-insoluble tau fractions from multiple cortical and subcortical regions was performed to evaluate the extent of tau pathology in PSP brains and to compare these data with the IHC findings from the same brain regions. All samples were dephosphorylated using alkaline phosphatase from E. coli, and representative images of nitrocellulose replicas probed with a mixture of P, MAb T46/T14 are shown in Figure 2A. In all PSP cases, sarkosyl-insoluble tau was most abundant in basal ganglia and brainstem compared with cortical regions; this is consistent with IHC studies reported here and elsewhere.2,5,8,13 A similar biochemical tau profile was also detected by 17025 and N-tau rabbit polyclonal antibodies (data not shown).

A quantitative Western blot tau profile for PSP was obtained, and the relative amounts of extracted insoluble tau from each brain region were presented as a percentage of the latter in basal ganglia (see Fig 2B). Unexpectedly, in more than 70% of PSP cases (19/23), the amount of insoluble tau in the cortical white matter was variable, but appreciably higher than in the gray matter from the same brain regions despite a low abundance of IHC-detectable tau inclusions in sections adjacent to the regions examined by Western blots here. Thus, although our IHC data confirm the previously reported abundance of microscopic tau pathology in PSP gray matter and the paucity of tau lesions in PSP white matter, our novel biochemical data demonstrate a previously unrecognized accumulation of pathological tau in PSP white matter.

Dephosphorylated samples from different brain regions were used to characterize the representation of 3R and 4R tau isoforms in soluble and sarkosyl-insoluble fractions from different PSP cases. Analysis of tau isoforms in multiple brain regions from 23 PSP cases showed a variable mixture of 3R and 4R tau isoforms in the cortical regions in 15 cases, whereas 4R tau species were overrepresented in 7 cases (see Fig 2A). Rabbit polyclonal E10-specific tau antibody demonstrated 4R tau isoforms in sarkosyl-insoluble preparation and the extent of pathology in E10-positive tau lesions (see Fig 2C). Furthermore, although all six tau isoforms were detected by a mixture of T14 and T46 MABs (see Fig 2C), E10-specific antibody selectively recognized only 4R tau isoforms in each sample and in the standard mixture of human recombinant tau proteins. IHC analysis of two PSP cases with 4R approximately the same as 3R and with 4R greater than 3R tau isoforms composition is shown in Figure 2D, and in both of these cases, E10-immunopositive neurofibrillary tangles in neurons, as well as glial tau inclusions and threads, were detected in cortical gray and white matter, as well as in brainstem. In PSP cases with 4R isoform overexpression, the number of E10-positive structures, particularly in the white matter, was notably higher.

Predominant expression of 4R tau isoforms was a distinct signature of pathological tau in brainstem structures, and in a subset of PSP cases, the 4R2N tau pathological isoform was more prominent than other tauopathies (Figs 3A, B). Interestingly, in the brainstem from AD brains, insoluble tau profile recapitulated a cortical pattern of tau isoforms with all six isoforms being present (see Fig 3A, bottom panel). To determine whether the ratio of tau isoforms is altered for normal tau in PSP, we evaluated soluble fractions from the cortex and the brainstem in PSP cases using a quantitative Western blot analysis. In contrast with different overrepresentation of 4R tau isoforms in sarkosyl-insoluble fractions from the cortex and the brainstem, the 4R:3R tau isoform ratio in corresponding soluble fractions from different PSP cases was approximately 1 (see Figs 3Aa and 3Ab). Finally, we compared the biochemical profile of spinal cord tau pathology in PSP with that in AD, which showed that the amounts of pathological tau proteins in PSP spinal cord were higher than in AD spinal cord, and there was a predominance of 4R tau in PSP spinal cord, whereas AD spinal cord showed similar amounts of 3R and 4R tau (see Fig 3C). Similar biochemical studies were performed on cortical gray and white matter from prospectively followed cognitively normal individuals, and these studies confirmed the absence of pathological tau proteins in these normal brain samples (see Supplementary Figure).

Representative Western blots comparing sarkosyl-insoluble tau extracted from PSP, CBD, and AD brains are shown in Figure 4, where distinct profiles of pathological tau for each disorder are evident. For example, in gray matter of AD cortex, the amounts of pathological tau were substantially higher than in PSP and CBD cortices, whereas in adjacent AD white matter, it was more moderate. Furthermore, cortical tau pathology in PSP was more moderate than AD or CBD, and the amount of pathological tau in PSP white matter was substantially higher than in the corresponding gray matter, which contrasts sharply with our IHC data on microscopically evident tau lesions (see Figs 1A–C). In CBD, the amounts of sarkosyl-insoluble tau correlated well with abundant tau-positive inclusions in both anatomical regions (see Figs 1 and 4B). Furthermore, representative Western blots of tau in fractions sequentially extracted with buffer of increasing strength (ie, from high-salt buffer to FA)
from the temporal cortex of PSP, CBD, and AD case are shown in Figure 5. These data show no significant difference in the soluble tau fractions among PSP, CBD, and AD, but there is a distinctive tau solubility profile in radioimmunoprecipitation assay, SDS, and FA fractions from each of these three tauopathies. Thus, the significant differences in quantities of insoluble tau detected in PSP, CBD, and AD suggest there is a differential solubility of pathological tau species in these tauopathies.

To further characterize the biochemical properties of pathological tau proteins in cortical gray and white matter in PSP, we analyzed the distribution of tau phosphoepitopes in different brain regions in PSP (Fig 6). Nondephosphorylated sarkosyl-insoluble samples were used for Western blot analysis. A mixture of tau-specific P$	ext{$_1$}$ MAb, T14/T46 was used to estimate a total sarkosyl-insoluble tau pool in the gray and white matter in two PSP cases. To demonstrate the relative level of site-specific phosphorylation and to compare it with the total amounts of insoluble tau, we re-probed the same nitrocellulose replicas with P$	ext{$_4$}$ MAb. PHF1 specific for Ser-396/404 and AT8 that recognize Ser202/Thr-205 detected predominantly 64 and 68kD tau species. Also, although the amounts of T14/T46-positive sarkosyl-insoluble tau in the corti-

Fig 3. The biochemical profile of pathological tau proteins differs in subcortical versus cortical regions of the progressive supranuclear palsy (PSP) brain. Sarkosyl-insoluble tau was extracted from different regions of the PSP brainstem and spinal cord, as well as from Alzheimer’s disease (AD) cases. (A, top panel) Western blot analysis of tau proteins in PSP brainstem and cortex. The total amounts of insoluble tau in the PSP brainstem are higher than in PSP cortex, and 4R tau isoforms (4R2N, 4R1N, 4R0N) predominate. (Middle panel) Quantitative Western blot analysis of soluble and insoluble tau in PSP. (Bottom panel) Comparative analysis of pathological tau in the brainstem and frontal cortex of two AD patients (AD 1 and AD 2). Asterisks identify lanes in which the amount of sample from AD cortex loaded onto the gel was only 20% of that from PSP cortex. (B) Schematic diagram of the brainstem to show the different levels at which samples were taken for study from the pons (P1 and P2) and medulla (M1-3). (C) Biochemical profile of spinal cord tau pathology in PSP (n = 3) and AD (n = 2). The amounts of pathological tau proteins in PSP spinal cord were higher than in AD spinal cord, and there is a predominance of 4R tau in PSP spinal cord, whereas AD spinal cord shows similar amounts of 3R and 4R tau. Fg = frontal cortex, gray matter; Fw = frontal cortex white matter; M1, 2, 3 = medulla levels 1, 2, and 3; P = pons; Tg = temporal cortex, gray matter; Tw = temporal cortex, white matter.
cal white matter was substantially higher than in the adjacent gray matter, PHF1 and AT8 immunoreactivity was significantly lower in the same samples, suggesting a reduction in the phosphorylation of selected phosphoepitopes in the white matter in PSP.

Finally, there were no differences in the apolipoprotein E genotypes or MAPT haplotypes among the PSP cases here with respect to the tau pathologies described earlier.

**Discussion**

In this study, we combined quantitative Western blot and IHC analyses of cortical and subcortical brain regions from 23 well-characterized PSP patients to characterize the profile and distribution pattern of tau pathologies and their isoform composition with particular emphasis on the gray versus white matter burden of these tau pathologies. Despite numerous comparative studies of PSP neuropathology, quantitative biochemical assessment of the distribution of tau pathology in gray versus white matter of multiple PSP brain regions has not been reported to complement information on microscopic tau lesions demonstrated by IHC. However, there is evidence that the biochemical detection of pathologically insoluble tau may not be reflected by microscopically evident tau lesions. Thus, our study was designed to address this issue in PSP by pursuing the multicenter collaborative investigation described here. Remarkably, although many of the observations in this large cohort of PSP cases confirmed previous studies of smaller numbers of PSP brains, we present novel data showing an unexpected abundance of biochemically detectable tau pathology in both white and gray matter despite that the insoluble tau in white matter was not apparent microscopically in sections of contiguous brain samples. Moreover, although we observed heterogeneity in the representation of pathological 3R and 4R tau isoforms in cortical versus subcortical regions across these PSP cases, biochemically detectable white matter tau pathology was a constant feature of PSP.

Although the burden of microscopic neocortical tau pathology correlates well with progressive cognitive decline and dementia in AD, only mild or moderate amounts of cortical gray matter tau lesions may be seen microscopically in the brains of PSP patients with dementia. Although the burden of neurofibrillary tangles and glial tau pathology in PSP patients in this study with cognitive impairment was higher than in patients with relatively preserved memory and cognition, cortical tau lesions were sparse compared with abundant tau lesions in subcortical brain regions. The presence of previously undetected abundant white matter tau pathology demonstrated here by Western blots, but not by IHC, are significant for understanding the pathogenesis and clinical manifestations of PSP because they imply that the heretofore unappreciated white matter tau pathology we demonstrate biochemically in PSP could underlie cognitive and motor impairments in PSP. These findings also may have diagnostic implications for PSP if, for example, they can be exploited in neuroimaging...
studies to detect white matter abnormalities that facilitate distinction of PSP from other clinically similar neurodegenerative disorders. However, further studies are needed to test these hypotheses.

Biochemically, the amounts of sarkosyl-insoluble tau in the white matter were higher than in adjacent gray matter in the majority of PSP cases, and this also has been described in CBD\(^9\) and Pick’s disease\(^{12}\). However, although the biochemical findings in CBD correlate well with the abundance of tau-immunopositive lesions detected by IHC in gray and white matter of CBD\(^9\) and similar correlations apply to PSP gray matter, enigmatically, this is not the case for white matter tau pathology in PSP.

Initially, the biochemical profile of pathological tau isoforms in PSP cortex was thought to be composed almost exclusively of 4R tau isoforms similar to CBD, but our data here, and other recent reports, indicate that there may be a variable mixture of pathological 3R- and 4R- tau isoforms in some PSP and CBD brains\(^{2,8,9}\). Based on our results, all PSP cases examined here could be divided into two major groups as a function of their cortical profile of pathological tau isoforms: (1) those with variable mixture of 3R and 4R tau isoforms, and (2) those with predominantly 4R tau isoforms. In contrast, 4R tau isoforms were significantly overrepresented in subcortical regions and brainstem regardless of the tau isoform profile in cortex of the same PSP brains.

Although there is a well-documented association between sporadic PSP and single nucleotide polymorphisms in the MAPT gene, similar associations have been reported for sporadic CBD, and it is unclear how these single nucleotide polymorphisms influence the onset or progression of PSP or the biochemical profile of pathological tau in PSP\(^{2,21,22}\). Consistent with these earlier observations, 21 of our 23 cases were found to have an H1/H1 and A0/A0 MAPT single nucleotide polymorphisms profile.

In conclusion, PSP is characterized by a distinct biochemical profile of pathological tau proteins, and al-
though this is similar to CBD, white matter tau pathology is far more abundant in CBD compared with PSP. Although white matter tau pathology is seen in other tauopathies in addition to PSP and CBD, it remains unclear what role glial and white matter tau pathology plays in mechanisms of brain degeneration in these tauopathies. However, it is likely that further insight into these issues could lead to better strategies for the diagnosis and treatment of PSP and related neurodegenerative tauopathies.

This work was supported by the NIH (National Institute of Aging, AG-10124, J.G.T.; AG08671, S.G.; AG-17586, V.M.-Y.L.), the Oxford Foundation, and the Marian S. Ware Alzheimer Program of the University of Pennsylvania. V.M.-Y.L. is the John H. Ware 3rd Professor for Alzheimer’s Disease Research, and J.Q.T. is the William Maul Measy-Truman G. Schnabel Jr. M.D. Professor of Geriatric Medicine and Gerontology.

We thank the families of patients who made this research possible, Dr M. Forman for helpful comments and discussions, and B.J. Cannon for technical assistance.

References